Karyopharm Therapeutics Inc. (KPTI) financial statements (2021 and earlier)

Company profile

Business Address 85 WELLS AVENUE
NEWTON, MA 02459
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments249263297352262268217
Cash and cash equivalents868210320212916876
Short-term investments163181194150133100142
Restricted cash and investments21211  
Receivables131110988 
Inventory, net of allowances, customer advances and progress billings322100 
Inventory322100 
Other undisclosed current assets9888756
Total current assets:277285318371279281223
Noncurrent Assets
Operating lease, right-of-use asset9101010111111
Property, plant and equipment2233333
Long-term investments and receivables2439493122 
Long-term investments2439493122 
Restricted cash and investments1111111
Total noncurrent assets:37526245161715
TOTAL ASSETS:313338380416295298238
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities57494845423529
Accounts payable4222131
Accrued liabilities53474644413228
Deferred revenue0001211
Debt   2222
Other liabilities1111110
Other undisclosed current liabilities222    
Total current liabilities:60535150463932
Noncurrent Liabilities
Long-term debt and lease obligation129128126125123122120
Long-term debt, excluding current maturities118116114112110108106
Operating lease, liability11121213131414
Liabilities, other than long-term debt   2233
Deferred revenue   2233
Other undisclosed noncurrent liabilities626261747474 
Total noncurrent liabilities:191201200200199199123
Total liabilities:263254250250245238156
Stockholders' equity
Stockholders' equity attributable to parent5184130166506082
Common stock0000000
Additional paid in capital1,1201,1091,1021,093923885866
Accumulated other comprehensive income (loss)111(0)(0)(0)0
Accumulated deficit(1,070)(1,026)(973)(926)(873)(825)(783)
Total stockholders' equity:5184130166506082
TOTAL LIABILITIES AND EQUITY:313338380416295298238

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues3521341818139
Cost of revenue
(Cost of Goods and Services Sold)
     (1) 
Other undisclosed gross profit(0)   1  
Gross profit:3521341819129
Operating expenses(72)(68)(74)(65)(61)(53)(51)
Other undisclosed operating income (loss)0   (1)1 
Operating loss:(37)(47)(40)(47)(43)(39)(42)
Nonoperating expense(6)(6)(6)(6)(5)(2)(2)
Investment income, nonoperating0111111
Interest and debt expense(7)(7)(7)(7)(6)(3)(3)
Other undisclosed income from continuing operations before equity method investments, income taxes27   16  
Loss from continuing operations before equity method investments, income taxes:(23)(60)(53)(59)(39)(44)(46)
Other undisclosed income (loss) from continuing operations before income taxes(20)777(9)33
Loss from continuing operations before income taxes:(43)(53)(46)(53)(49)(41)(43)
Income tax expense(0)(0)(0)(0)(0)(0)(0)
Net loss available to common stockholders, diluted:(43)(53)(46)(53)(49)(41)(43)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(43)(53)(46)(53)(49)(41)(43)
Comprehensive loss:(43)(53)(46)(53)(49)(41)(43)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)1(0)(0)(0)0
Comprehensive loss, net of tax, attributable to parent:(44)(54)(45)(53)(49)(41)(43)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: